-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Ft5mBZcvueaA7/mYiFwmteKjeSIrYeCiny7Cj6bsDcYY6snWhWZPyzqoL/AKViVp
 yAZF+vWf5c/kE5EoaUJfGQ==

<SEC-DOCUMENT>0000878088-09-000010.txt : 20090109
<SEC-HEADER>0000878088-09-000010.hdr.sgml : 20090109
<ACCEPTANCE-DATETIME>20090109164216
ACCESSION NUMBER:		0000878088-09-000010
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20090108
FILED AS OF DATE:		20090109
DATE AS OF CHANGE:		20090109

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			ABERNATHY JOHN D
		CENTRAL INDEX KEY:			0001017996
		STATE OF INCORPORATION:			DC
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-10827
		FILM NUMBER:		09519208

	BUSINESS ADDRESS:	
		BUSINESS PHONE:		5082874275

	MAIL ADDRESS:	
		STREET 1:		C/O PATTON BOGGS, L.L.P.
		STREET 2:		2550 M STREET NW
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PAR PHARMACEUTICAL COMPANIES, INC.
		CENTRAL INDEX KEY:			0000878088
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				223122182
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		300 TICE BOULEVARD
		CITY:			WOODCLIFF LAKE
		STATE:			NJ
		ZIP:			07677
		BUSINESS PHONE:		201-802-4000

	MAIL ADDRESS:	
		STREET 1:		300 TICE BOULEVARD
		CITY:			WOODCLIFF LAKE
		STATE:			NJ
		ZIP:			07677

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHARMACEUTICAL RESOURCES INC
		DATE OF NAME CHANGE:	19940526
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>primary_doc.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2009-01-08</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000878088</issuerCik>
        <issuerName>PAR PHARMACEUTICAL COMPANIES, INC.</issuerName>
        <issuerTradingSymbol>PRX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001017996</rptOwnerCik>
            <rptOwnerName>ABERNATHY JOHN D</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PAR PHARMACEUTICAL COMPANIES, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>300 TICE BLVD</rptOwnerStreet2>
            <rptOwnerCity>WOODCLIFF LAKE</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07677</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Restricted Stock Units</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0</value>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2009-01-08</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>7657</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2010-01-08</value>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>7657</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>19563</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Pursuant to the Amended and Restated 1997 Directors' Stock and Deferred Fee Plan, the Reporting Person was granted a Restricted Stock Award of the number of shares of the Issuer's common stock having an aggregate Fair Market Value equal to $100,000 on the date of grant.  The Fair Market Value of each Restricted Stock Unit is equal to the closing price of the Issuer's common stock as reported by The New York Stock Exchange, Inc. on the date of grant, which was $13.06.  The Restricted Stock Units vest one year from the anniversary of the date of grant.  Each stock unit is the economic equivalent of one share of common stock, but the shares of common stock are distributed only upon termination of the Reporting Person's services as a director of the Issuer.</footnote>
    </footnotes>

    <remarks>LIMITED POWER OF ATTORNEY: KNOW ALL MEN BY THESE PRESENTS, that the undersigned does hereby constitute and appoint MARIAN E. GUSTAFSON with full power to act, as his/her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him/her and in his/her name, place and stead, in any and all capacities, and to do any and all acts and things in his/her name and on his/her behalf, to execute any and all documents and instruments, which said attorney-in-fact may deem necessary or advisable to enable him/her to comply with the reporting requirements pursuant to Section 16 of the Securities Exchange Act of 1934, as amended, including but not limited to Form 4-Statement of Changes in Beneficial Ownership and Form 5-Annual Statement of Changes in Beneficial Ownership, relating to his/her ownership in Par Pharmaceutical Companies, Inc. (the &quot;Company&quot;) for the period October 1, 2008 through and including September 30, 2009; and to file the same, and all oth
er documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that the said attorney-in-fact and agent may lawfully do or cause to be done by virtue thereof. /s/ John D. Abernathy  Dated: Sept. 15, 2008</remarks>

    <ownerSignature>
        <signatureName>/s/ Marian E. Gustafson for John D. Abernathy</signatureName>
        <signatureDate>2009-01-09</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----